Adding Perioperative Pembrolizumab to Standard of Care Improves Outcomes in Patients with Newly Diagnosed Head and Neck Cancers

The RAPCHEM study's 10-year follow-up shows risk-based radiotherapy de-escalation after primary systemic therapy is safe for early breast cancer patients. Fleur Mauritz MD from MAASTRO presented these findings at EBCC 2026, demonstrating long-term safety of reduced radiation in select patients.

The LORD trial finds active surveillance is as effective as standard therapy for ER-positive, HER2-negative, grade 1–2 DCIS. Randomisation was stopped early due to reassuring results. Jelle Wesseling MD PhD from the Netherlands Cancer Institute presented the findings at EBCC 2026 in Barcelona.

Circulating tumour DNA outperforms clinical markers like pathological complete remission in predicting relapse after neoadjuvant therapy for early breast cancer. Elisa Agostinetto MD from Institut Jules Bordet presented this prospective pooled analysis from Belgium and Italy at EBCC 2026.

The OPBC-09 PRExRT study shows polyurethane-coated breast implants reduce capsular contracture risk vs uncoated implants after mastectomy with immediate pre-pectoral reconstruction and radiotherapy. Kerstin Wimmer MD from Medical University of Vienna presented the results at EBCC 2026 in Barcelona.

The OASIS-4 phase III trial shows elinzanetant, a dual neurokinin receptor antagonist, significantly reduces hot flashes in breast cancer patients on endocrine therapy. Fatima Cardoso MD from Centre Antoine Lacassagne in Nice reported rapid onset and sustained effects over 52 weeks at EBCC 2026.

BRAVE-HEART Study Shows How Breath-Holding System Halves Coronary Radiation Dose During Left Breast Irradiation An interview with: Elisabetta Bonzano MD PhD, IRCCS San Matteo Polyclinic Foundation, Ra

European Breast Cancer Conference: Focus on Therapy De-escalation and Individualization An interview with: Philip Poortmans MD PhD, Radiation Oncology Department, University of Antwerp & Iridium N

Molecular Test Distinguishes Ipsilateral Second Primary from Recurrent Breast Cancer An interview with: Tess Snellen MD, Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital, Departmen